Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study.

Takahashi N, Yamamoto T, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Ishikawa Y, Kozumi M, Katagiri Y, Tasaka S, Takeda K, Takeda K, Dobashi S, Jingu K.

J Radiat Res. 2016 Jul 15. [Epub ahead of print]

2.

Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.

Yamamoto T, Kadoya N, Takeda K, Matsushita H, Umezawa R, Sato K, Kubozono M, Ito K, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Onishi H, Jingu K.

Radiat Oncol. 2016 May 26;11:72. doi: 10.1186/s13014-016-0651-5.

3.

Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols.

Umezawa R, Jingu K, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K, Ariga H, Nemoto K, Yamada S.

BMC Cancer. 2015 Oct 27;15:813. doi: 10.1186/s12885-015-1836-2.

4.

Chemoradiotherapy for T4 and/or M1 lymph node esophageal cancer: experience since 2000 at a high-volume center in Japan.

Jingu K, Umezawa R, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Kozumi M, Takahashi N, Katagiri Y, Kadoya N, Takeda K.

Int J Clin Oncol. 2016 Apr;21(2):276-82. doi: 10.1007/s10147-015-0896-2. Epub 2015 Sep 1.

PMID:
26324841
5.

Treatment outcomes of patients with FIGO Stage I/II uterine cervical cancer treated with definitive radiotherapy: a multi-institutional retrospective research study.

Ariga T, Toita T, Kato S, Kazumoto T, Kubozono M, Tokumaru S, Eto H, Nishimura T, Niibe Y, Nakata K, Kaneyasu Y, Nonoshita T, Uno T, Ohno T, Iwata H, Harima Y, Wada H, Yoshida K, Gomi H, Numasaki H, Teshima T, Yamada S, Nakano T.

J Radiat Res. 2015 Sep;56(5):841-8. doi: 10.1093/jrr/rrv036. Epub 2015 Jun 24. Erratum in: J Radiat Res. 2016 Jan;57(1):101.

6.

Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.

Yamamoto T, Kadoya N, Shirata Y, Kaneta T, Koto M, Umezawa R, Ishikawa Y, Kubozono M, Sugawara T, Matsushita H, Abe K, Takeda K, Jingu K.

Ann Nucl Med. 2015 Oct;29(8):666-73. doi: 10.1007/s12149-015-0991-5. Epub 2015 Jun 4.

PMID:
26040413
7.

Assessment of myocardial metabolic disorder associated with mediastinal radiotherapy for esophageal cancer -a pilot study.

Umezawa R, Takanami K, Kadoya N, Nakajima Y, Saito M, Ota H, Matsushita H, Sugawara T, Kubozono M, Yamamoto T, Ishikawa Y, Takeda K, Taki Y, Takase K, Jingu K.

Radiat Oncol. 2015 Apr 21;10:96. doi: 10.1186/s13014-015-0410-z.

8.

Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy.

Yamamoto T, Kadoya N, Shirata Y, Koto M, Sato K, Matsushita H, Sugawara T, Umezawa R, Kubozono M, Ishikawa Y, Kozumi M, Takahashi N, Ito K, Katagiri Y, Takeda K, Jingu K.

Radiat Oncol. 2015 Feb 7;10:35. doi: 10.1186/s13014-015-0343-6.

9.

Outcomes after stereotactic body radiotherapy for lung tumors, with emphasis on comparison of primary lung cancer and metastatic lung tumors.

Yamamoto T, Jingu K, Shirata Y, Koto M, Matsushita H, Sugawara T, Kubozono M, Umezawa R, Abe K, Kadoya N, Ishikawa Y, Kozumi M, Takahashi N, Takeda K, Takai Y.

BMC Cancer. 2014 Jun 23;14:464. doi: 10.1186/1471-2407-14-464.

10.

Evaluation of various deformable image registration algorithms for thoracic images.

Kadoya N, Fujita Y, Katsuta Y, Dobashi S, Takeda K, Kishi K, Kubozono M, Umezawa R, Sugawara T, Matsushita H, Jingu K.

J Radiat Res. 2014 Jan 1;55(1):175-82. doi: 10.1093/jrr/rrt093. Epub 2013 Jul 17.

11.

Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study.

Jingu K, Matsushita H, Takeda K, Umezawa R, Takahashi C, Sugawara T, Kubozono M, Abe K, Tanabe T, Shirata Y, Yamamoto T, Ishikawa Y, Nemoto K.

BMC Cancer. 2012 Nov 22;12:542. doi: 10.1186/1471-2407-12-542.

12.

Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.

Shirata Y, Jingu K, Koto M, Kubozono M, Takeda K, Sugawara T, Kadoya N, Matsushita H.

Radiat Oncol. 2012 Oct 31;7:182. doi: 10.1186/1748-717X-7-182.

13.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

14.

Intraoperative radiotherapy for pancreatic cancer: 30-year experience in a single institution in Japan.

Jingu K, Tanabe T, Nemoto K, Ariga H, Umezawa R, Ogawa Y, Takeda K, Koto M, Sugawara T, Kubozono M, Shimizu E, Abe K, Yamada S.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e507-11. doi: 10.1016/j.ijrobp.2012.01.024. Epub 2012 Mar 22.

PMID:
22445002
15.

Long-term results of radiochemotherapy for solitary lymph node metastasis after curative resection of esophageal cancer.

Jingu K, Ariga H, Nemoto K, Narazaki K, Umezawa R, Takeda K, Koto M, Sugawara T, Kubozono M, Miyata G, Onodera K, Yamada S.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):172-7. doi: 10.1016/j.ijrobp.2011.06.1978. Epub 2011 Nov 11.

PMID:
22079727
16.

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml.

Umezawa R, Ariga H, Ogawa Y, Jingu K, Matsushita H, Takeda K, Fujimoto K, Sakayauchi T, Sugawara T, Kubozono M, Narazaki K, Shimizu E, Takai Y, Yamada S.

Radiat Oncol. 2011 Nov 5;6:150. doi: 10.1186/1748-717X-6-150.

17.

Predicting the severity of acute urinary toxicity after brachytherapy with iodine-125 for localized prostate cancer.

Takeda K, Jingu K, Koto M, Fujimoto K, Narazaki K, Kubozono M, Saito H, Yamada S, Mitsuduka K, Ishidoya S, Ariga H, Arai Y, Yamada S.

Tohoku J Exp Med. 2011;223(1):55-60.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk